Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma

N. Niitsu, M. Okamoto, J. I. Tamaru, Tadashi Yoshino, N. Nakamura, S. Nakamura, K. Ohshima, H. Nakamine, M. Hirano

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) comprises ∼10% of DLBCLs, and it is associated with poor prognosis. The clinicopathologic characteristics and prognosis of CD5-negative (CD5-) DLBCL and CD5+ DLBCL were compared. Patients and methods: The subjects were 607 DLBCL patients in whom cell surface markers could be analyzed, among 930 consecutive patients registered in the Adult Lymphoma Treatment Study Group between 1998 and 2008.Results: In all, 102 patients (16.8%) had CD5+ DLBCL. Compared with CD5- DLBCL, CD5+ DLBCL was more closely associated with elevated serum lactate dehydrogenase level, advanced stage, poor performance status, extranodal sites, CD10-, BCL-2+, MUM1+, and nongerminal center B-cell type. The 5-year overall survival (OS) rates of CD5+ DLBCL (n = 102) and CD5- DLBCL (n = 505) were 55% and 65%, respectively (P = 0.032), with 5-year progression-free survival (PFS) rates of 52% and 61%, respectively (P = 0.041). In the CD5+ DLBCL patients, the addition of rituximab to chemotherapy significantly improved PFS (4-year PFS, 47.4% versus 62.5%), but not OS (4-year OS, 57.8% versus 63.5%).Conclusions: For CD5+ DLBCL, the addition of rituximab to chemotherapy significantly improved the PFS, but not OS. Therefore, it is thought that a new treatment strategy is necessary for CD5+ DLBCL.

Original languageEnglish
Pages (from-to)2069-2074
Number of pages6
JournalAnnals of Oncology
Volume21
Issue number10
DOIs
Publication statusPublished - Mar 15 2010
Externally publishedYes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Disease-Free Survival
B-Cell Lymphoma
Survival
Rituximab
Survival Rate
L-Lactate Dehydrogenase
Lymphoma
B-Lymphocytes

Keywords

  • CD5-positive diffuse large B-cell lymphoma
  • CyclOBEAP
  • Nongerminal center B-cell type
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. / Niitsu, N.; Okamoto, M.; Tamaru, J. I.; Yoshino, Tadashi; Nakamura, N.; Nakamura, S.; Ohshima, K.; Nakamine, H.; Hirano, M.

In: Annals of Oncology, Vol. 21, No. 10, 15.03.2010, p. 2069-2074.

Research output: Contribution to journalArticle

Niitsu, N. ; Okamoto, M. ; Tamaru, J. I. ; Yoshino, Tadashi ; Nakamura, N. ; Nakamura, S. ; Ohshima, K. ; Nakamine, H. ; Hirano, M. / Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. In: Annals of Oncology. 2010 ; Vol. 21, No. 10. pp. 2069-2074.
@article{2aeb686ec0e04cdc9ed9bd37cf2715c3,
title = "Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma",
abstract = "Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) comprises ∼10{\%} of DLBCLs, and it is associated with poor prognosis. The clinicopathologic characteristics and prognosis of CD5-negative (CD5-) DLBCL and CD5+ DLBCL were compared. Patients and methods: The subjects were 607 DLBCL patients in whom cell surface markers could be analyzed, among 930 consecutive patients registered in the Adult Lymphoma Treatment Study Group between 1998 and 2008.Results: In all, 102 patients (16.8{\%}) had CD5+ DLBCL. Compared with CD5- DLBCL, CD5+ DLBCL was more closely associated with elevated serum lactate dehydrogenase level, advanced stage, poor performance status, extranodal sites, CD10-, BCL-2+, MUM1+, and nongerminal center B-cell type. The 5-year overall survival (OS) rates of CD5+ DLBCL (n = 102) and CD5- DLBCL (n = 505) were 55{\%} and 65{\%}, respectively (P = 0.032), with 5-year progression-free survival (PFS) rates of 52{\%} and 61{\%}, respectively (P = 0.041). In the CD5+ DLBCL patients, the addition of rituximab to chemotherapy significantly improved PFS (4-year PFS, 47.4{\%} versus 62.5{\%}), but not OS (4-year OS, 57.8{\%} versus 63.5{\%}).Conclusions: For CD5+ DLBCL, the addition of rituximab to chemotherapy significantly improved the PFS, but not OS. Therefore, it is thought that a new treatment strategy is necessary for CD5+ DLBCL.",
keywords = "CD5-positive diffuse large B-cell lymphoma, CyclOBEAP, Nongerminal center B-cell type, Rituximab",
author = "N. Niitsu and M. Okamoto and Tamaru, {J. I.} and Tadashi Yoshino and N. Nakamura and S. Nakamura and K. Ohshima and H. Nakamine and M. Hirano",
year = "2010",
month = "3",
day = "15",
doi = "10.1093/annonc/mdq057",
language = "English",
volume = "21",
pages = "2069--2074",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma

AU - Niitsu, N.

AU - Okamoto, M.

AU - Tamaru, J. I.

AU - Yoshino, Tadashi

AU - Nakamura, N.

AU - Nakamura, S.

AU - Ohshima, K.

AU - Nakamine, H.

AU - Hirano, M.

PY - 2010/3/15

Y1 - 2010/3/15

N2 - Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) comprises ∼10% of DLBCLs, and it is associated with poor prognosis. The clinicopathologic characteristics and prognosis of CD5-negative (CD5-) DLBCL and CD5+ DLBCL were compared. Patients and methods: The subjects were 607 DLBCL patients in whom cell surface markers could be analyzed, among 930 consecutive patients registered in the Adult Lymphoma Treatment Study Group between 1998 and 2008.Results: In all, 102 patients (16.8%) had CD5+ DLBCL. Compared with CD5- DLBCL, CD5+ DLBCL was more closely associated with elevated serum lactate dehydrogenase level, advanced stage, poor performance status, extranodal sites, CD10-, BCL-2+, MUM1+, and nongerminal center B-cell type. The 5-year overall survival (OS) rates of CD5+ DLBCL (n = 102) and CD5- DLBCL (n = 505) were 55% and 65%, respectively (P = 0.032), with 5-year progression-free survival (PFS) rates of 52% and 61%, respectively (P = 0.041). In the CD5+ DLBCL patients, the addition of rituximab to chemotherapy significantly improved PFS (4-year PFS, 47.4% versus 62.5%), but not OS (4-year OS, 57.8% versus 63.5%).Conclusions: For CD5+ DLBCL, the addition of rituximab to chemotherapy significantly improved the PFS, but not OS. Therefore, it is thought that a new treatment strategy is necessary for CD5+ DLBCL.

AB - Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) comprises ∼10% of DLBCLs, and it is associated with poor prognosis. The clinicopathologic characteristics and prognosis of CD5-negative (CD5-) DLBCL and CD5+ DLBCL were compared. Patients and methods: The subjects were 607 DLBCL patients in whom cell surface markers could be analyzed, among 930 consecutive patients registered in the Adult Lymphoma Treatment Study Group between 1998 and 2008.Results: In all, 102 patients (16.8%) had CD5+ DLBCL. Compared with CD5- DLBCL, CD5+ DLBCL was more closely associated with elevated serum lactate dehydrogenase level, advanced stage, poor performance status, extranodal sites, CD10-, BCL-2+, MUM1+, and nongerminal center B-cell type. The 5-year overall survival (OS) rates of CD5+ DLBCL (n = 102) and CD5- DLBCL (n = 505) were 55% and 65%, respectively (P = 0.032), with 5-year progression-free survival (PFS) rates of 52% and 61%, respectively (P = 0.041). In the CD5+ DLBCL patients, the addition of rituximab to chemotherapy significantly improved PFS (4-year PFS, 47.4% versus 62.5%), but not OS (4-year OS, 57.8% versus 63.5%).Conclusions: For CD5+ DLBCL, the addition of rituximab to chemotherapy significantly improved the PFS, but not OS. Therefore, it is thought that a new treatment strategy is necessary for CD5+ DLBCL.

KW - CD5-positive diffuse large B-cell lymphoma

KW - CyclOBEAP

KW - Nongerminal center B-cell type

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=77956939958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956939958&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq057

DO - 10.1093/annonc/mdq057

M3 - Article

C2 - 20231297

AN - SCOPUS:77956939958

VL - 21

SP - 2069

EP - 2074

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -